Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | SVP, Accounting | January 06, 2017 | January 10, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intellia Therapeutics, Inc.
Report date January 06, 2017 · Filed January 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2027-01-05 | Direct | 28,500 |
Reported balance
After 2017-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-06 · Grant · Acquired 28,500 · Balance 28,500 F1: This option was granted on January 6, 2017 with respect to 28,500 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 6, 2017 with respect to 28,500 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2017 Filed Jan 10, 2017 20:12 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 28,500 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001209191-17-003293 · doc4.xml · derivative · entry 1 Heifner Nicole · CIK 0001670999 · SVP, Accounting 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2027-01-05 F1 · derivative.exercise_date: This option was granted on January 6, 2017 with respect to 28,500 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.